688098.SH
申联生物
SSE · Healthcare · Biotechnology · CN
CNY 8.00
−3.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 272.1M | 288.3M | 303.4M | 301.5M | 328.6M |
| Cost of Revenue | 115.1M | 124.5M | 120.6M | 87.9M | 81.4M |
| Gross Profit | 157.0M | 163.8M | 182.8M | 213.6M | 247.2M |
| Operating Expenses | |||||
| R&D Expense | 42.3M | 44.8M | 49.4M | 44.5M | 39.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 50.9M | 53.5M | 55.2M | 50.3M | 55.6M |
| Selling & Marketing Expense | 74.3M | 80.8M | 100.7M | 84.4M | 73.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 170.8M | 182.1M | 208.9M | 182.7M | 170.2M |
| Cost and Expenses | 285.9M | 306.6M | 329.5M | 270.7M | 251.6M |
| Operating Income (EBIT) | (26.6M) | (27.9M) | (56.5M) | 36.1M | 75.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (25.0M) | (26.3M) | (56.8M) | 36.3M | 74.6M |
| Income Tax Expense | (1.7M) | (1.3M) | (8.0M) | 6.4M | 13.6M |
| Bottom Line | |||||
| Net Income | (19.2M) | (20.5M) | (44.7M) | 31.5M | 61.1M |
| Earnings from Cont. Ops | (23.3M) | (25.0M) | (48.7M) | 29.9M | 61.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (19.2M) | (20.5M) | (44.7M) | 31.5M | 61.1M |
| Per Share | |||||
| Basic EPS | (CN¥0.04) | (CN¥0.05) | (CN¥0.11) | CN¥0.08 | CN¥0.15 |
| Diluted EPS | (CN¥0.04) | (CN¥0.05) | (CN¥0.11) | CN¥0.08 | CN¥0.15 |
| Revenue Per Share | — | CN¥0.70 | CN¥0.75 | CN¥0.77 | CN¥0.81 |
| Shares | |||||
| Basic Shares Outstanding | — | 409.9M | 406.7M | 394.0M | 407.3M |
| Diluted Shares Outstanding | — | 409.9M | 406.7M | 394.0M | 407.3M |
| Profitability Metrics | |||||
| EBITDA | — | 47.2M | 11.6M | 99.3M | 132.2M |
| D&A | — | 75.0M | 68.1M | 63.2M | 56.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026